Brivaracetam effectiveness and patient-reported outcomes in clinical practice: Data from a 12-month prospective, observational study in the United States

Authors

Hina Dave, Baylor College of Medicine Medical Campus, Houston, TX, USA. Electronic address: hina.dave@bcm.edu.
Michael R. Sperling, Thomas Jefferson University, Philadelphia, PA, USA. Electronic address: michael.sperling@jefferson.edu.
Hamada Hamid Altalib, Yale School of Medicine, Yale University, New Haven, CT, USA. Electronic address: hamada.hamid@yale.edu.
Heidi Henninger, Maine Medical Center, Portland, ME, USA; Present address: UCB, Smyrna, GA, USA. Electronic address: Heidi.Henninger@ucb.com.
Roger J. Porter, Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: rjportermd@gmail.com.

Document Type

Article

Publication Date

7-3-2025

Journal Title

Epilepsy & behavior : E&B

Abstract

OBJECTIVE: Evaluate real-world effectiveness, patient-reported outcomes (PROs), and safety/tolerability of brivaracetam in patients (≥16 years) with focal-onset seizures currently receiving ≥ 1 antiseizure medication (ASM), and with historical or current use of levetiracetam, lamotrigine, oxcarbazepine, and/or carbamazepine. METHODS: EP0088 was a 12-month, prospective, observational study of brivaracetam in a clinical practice setting in the US. Primary study outcome was brivaracetam retention at 12 months after brivaracetam initiation. Effect of brivaracetam on patients' perceptions of their health was assessed using Patient-Reported Outcomes Measurement Information System (PROMIS) short forms and Seizure-Related Disability Assessment Scale (SERDAS). Safety outcomes included incidence of treatment-emergent adverse events (TEAEs). RESULTS: 254 patients (mean age: 44.3 years; median duration of epilepsy: 17.3 years) received ≥ 1 brivaracetam dose (Safety Set; SS). Patients had a median of 3.0 historical and 2.0 concomitant ASMs (SS). For all patients (SS), including those who dropped out with unknown brivaracetam treatment status, 12-month brivaracetam retention was 57.1 % (n = 145/254); in patients with known brivaracetam treatment status (post hoc analysis), 12-month brivaracetam retention was 72.1 % (n = 145/201). Slight improvements in mean PROMIS T-scores, and improvements in mean SERDAS scores, were seen by month 1.5, and generally maintained up to 12 months (Full Analysis Set). 49.6 % of patients reported ≥ 1 TEAE, 38.2 % had drug-related TEAEs, and 16.1 % discontinued due to TEAEs (SS). CONCLUSIONS: Brivaracetam was effective in patients with difficult-to-control focal-onset seizures; as shown by brivaracetam retention at 12 months. Improvements in PROs were seen early. Brivaracetam was well-tolerated and no new safety signals were observed.

First Page

110565

Recommended Citation

Dave, Hina; Sperling, Michael R.; Altalib, Hamada Hamid; Henninger, Heidi; and Porter, Roger J., "Brivaracetam effectiveness and patient-reported outcomes in clinical practice: Data from a 12-month prospective, observational study in the United States" (2025). MaineHealth Maine Medical Center. 4080.
https://knowledgeconnection.mainehealth.org/mmc/4080